Skip to main content
Main navigation
Home
About pCPA
Who We Are
Governance
FAQs
Negotiations
Recent Updates
Forms and Publications
Brand Name Drugs
Negotiations Status
Negotiation Process
Generic Drugs
Biologics/Biosimilars
Contact Us
EN
FR
Brilinta (ticagrelor)
pCPA File Number:
21126
Negotiation Status:
Concluded with an LOI
Indication(s):
secondary prevention of atherothrombotic events
Sponsor/Manufacturer:
AstraZeneca Canada Inc.
CADTH Project Number:
Not Applicable
pCPA Engagement Letter Issued:
2019-05-17
Negotiation Process Concluded:
2019-06-19